Vancomycin-resistant Enterococcus faecium (VREF) is an opportunistic pathogen, which causes infections among severely ill, hospitalized patients, in whom it is likely to increase the risk of progressive local or systemic disease and to worsen the prognosis. Because these organisms are often highly resistant to penicillin, ampicillin and many other antimicrobials including the glycopeptides, there are few proven therapeutic alternatives for the treatment of infection caused by VREF. Quinupristin/dalfopristin is highly active against VREF in vitro. A prolonged post-antibiotic effect, good polymorphonuclear leucocyte/macrophage penetration and slow release, and active metabolites allow this agent to be used with an 8 or 12 h dosing interval. The combined results from a Phase III non-comparative study and an emergency-use study of quinupristin/dalfopristin for the treatment of VREF infection produced a clinical response rate (cure or improvement) in 142 (73.6%) of 193 clinically evaluable patients. The baseline pathogen was eradicated or presumed eradicated from 110 of 156 (70.5%) bacteriologically evaluable patients. Fifty-two per cent of the severely ill patients in these two studies died, but no death was attributed to quinupristin/dalfopristin therapy. The most common adverse event was arthralgia (9.1%). Quinupristin/dalfopristin has demonstrated efficacy for the treatment of serious VREF infections, including those that have failed conventional therapy. 
Introduction
The treatment of infection caused by vancomycin-resistant Enterococcus faecium (VREF) is a significant challenge. The purpose of this review is to examine the efficacy of a new intravenous streptogramin antibiotic, quinupristin/ dalfopristin, for the therapy of VREF infections.
Glycopeptide resistance in E. faecium
Enterococci are intrinsically resistant to the penicillins, cephalosporins, carbapenems, clindamycin, co-trimoxazole, tetracyclines and the aminoglycosides. During the last 20 years enterococci have acquired high-level resistance to aminoglycosides (related to production of aminoglycosidemodifying enzymes) and to glycopeptides (related to an alteration of the cell-wall target site) and many other antimicrobial agents. [1] [2] [3] Glycopeptide resistance in E. faecium is mediated via a group of genes that enable synthesis of cell-wall precursors with a D-alanine-D-lactate terminus instead of the usual D-alanine-D-alanine terminus. The glycopeptides are unable to bind to this altered cell-wall precursor and, therefore, to interrupt cell-wall synthesis. 4, 5 VREF exhibit at least three different phenotypes, designated VanA, VanB and VanD. 5, 6 The two most common resistance phenotypes, VanA and VanB, have been found on transmissible genetic elements, which may be present in plasmids or inserted in the chromosome. VanA strains are highly resistant to both vancomycin and teicoplanin, and resistance is inducible by either of these glycopeptides. VanB strains are resistant to vancomycin but susceptible to teicoplanin, and resistance is induced only by vancomycin. The VanD phenotype was identified more recently and demonstrates only modest resistance to both glycopeptides. This phenotype has been characterized in only a few strains of E. faecium. 5, 6 Resistance in these strains is inducible by vancomycin but not teicoplanin and the genes
Epidemiological and clinical consequences
In Europe, vancomycin-resistant enterococcal strains were initially discovered in haemodialysis patients but soon thereafter were found in farm animals, in the stools of asymptomatic carriers and in specimens taken from patients with community-acquired infections. Avoparcin, a glycopeptide used as an agricultural feed supplement, was implicated as a contributor to the acquisition of VREF in farm animals, 8 and there has since been a temporary ban on glycopeptides in animal feeds in much of Europe. 2, 3 In the USA, on the other hand, the emergence of VREF strains was associated with the widespread use of vancomycin and a wide variety of broad-spectrum antimicrobial agents for the treatment of nosocomial infections. 3 The proportion of E. faecium isolates resistant to vancomycin has risen rapidly in the USA. Among patients in intensive care units, 0.4% of enterococci were resistant to vancomycin in 1989; this figure had risen to almost 14% by 1993. 9 In the recent SCOPE survey, which included 364 cases of enterococcal bacteraemia from a geographically diverse group of patients in the USA, 47% of E. faecium infections were caused by vancomycin-resistant strains. 10 VREF is an opportunistic pathogen, which primarily causes infections among the most vulnerable patients: severely ill, hospitalized patients, such as those with severe persistent immunosuppression or severe underlying disease, those recovering from extensive surgery (especially intra-abdominal or thoracic surgery) and recent liver or bone marrow transplant recipients. 2, [11] [12] [13] Other risk factors for infection or colonization with VREF include: (i) the resistance rate at the institution; (ii) proximity to another patient with VREF; (iii) the duration of hospitalization; and (iv) previous antibiotic exposure (particularly to cephalosporins, vancomycin or metronidazole).
14 VREF bloodstream or postoperative wound infection is likely to increase the risk of progressive local or systemic disease, and to worsen the prognosis. The risk of mortality attributable to glycopeptide resistance in enterococci has varied, in part because of differences in patient populations and study methodologies (Table I) . 14 
Therapeutic alternatives to vancomycin
There are few proven therapeutic alternatives to the glycopeptides for the treatment of infection caused by VREF. Occasionally a strain of VREF remains susceptible to high doses of ampicillin or penicillin (if the MICs are р6 4 m g / L ) . 1 5 Anecdotal reports indicate varying degrees of success with several improvised regimens of combinations of older antibiotics, such as chloramphenicol, rifampicin, bacitracin (oral or topical therapy only), doxycycline and novobiocin, as well as combinations of variousl a c t a m s . 1 6 -2 1 However, both the development of resistance and/or clinical failure are common with these older agents, and controlled studies documenting efficacy are lacking. In contrast, quinupristin/dalfopristin, a new intravenous semisynthetic streptogramin antibiotic, has demonstrated efficacy in the treatment of VREF infections, including those that have failed therapy with other antimicrobial agents.
Quinupristin/dalfopristin in VREF infections
Quinupristin/dalfopristin is highly active against VREF in vitro. 22 Of 1305 strains tested in vitro in preclinical studies, 95% were susceptible to quinupristin/dalfopristin (MICs р1 mg/L) and 51% had quinupristin/dalfopristin MICs of р0.5 mg/L, but only 6% were susceptible to ciprofloxacin (MICs р1 mg/L); doxycycline and chloramphenicol also had reduced activity against these VREF strains, with MIC 90 values of 16 and 8 mg/L, respectively (Table II) . Qualitatively (Table II) . It is important to note, however, that while E. faecium are susceptible, quinupristin/dalfopristin is not active against Enterococcus faecalis, including vancomycin-resistant strains. Initiation of the Phase III development programme for quinupristin/dalfopristin coincided with the emergence of growing numbers of infections due to VREF and other Gram-positive pathogens for which no other treatment option was appropriate (e.g. because of in-vitro resistance of the infecting organism or because of the patient's intolerance to, or failure on, all available appropriate agents). Thus, the efficacy and safety of quinupristin/dalfopristin in the treatment of VREF infection was assessed in both a non-comparative Phase III study conducted at 44 centres in the USA, and a non-comparative emergency-use study conducted worldwide. 23 A total of 396 patients with VREF infection were enrolled in the USA, UK, France, Canada, Germany and Israel. Patients were enrolled based on one or more of nine predefined indications if they had a positive culture for VREF (or for a pathogen presumed susceptible to quinupristin/dalfopristin), signs and symptoms consistent with active Gram-positive infection, and there was no existing alternative therapy because: the pathogen was resistant to all clinically appropriate antibiotics; and/or the patient was intolerant of all clinically appropriate antibiotics; and/or treatment failure was documented with all clinically appropriate antibiotics. The recommended dose of quinupristin/dalfopristin was 7.5 mg/kg every 8 h. The test-of-cure assessment was performed 3-21 days after the end of treatment with quinupristin/dalfopristin, or at the end-of-treatment visit if the patient did not progress to follow-up.
These patients were generally very ill at baseline: onehalf suffered from renal failure; one-half were bacteraemic; more than one-quarter were diabetic; more than onequarter were post-transplantation and one-quarter were on mechanical ventilation. In addition, malnutrition and chronic liver disease were each present in 10% or more of the study population.
The mean duration of therapy (Ϯ S.D.) was 14. (Table III) . The mortality rate was 52% in this severely ill patient population, but no death was attributed to quinupristin/ dalfopristin therapy. A treatment-related adverse event occurred in 28.5% (113/396) of the patients enrolled in the Phase III study (Table IV) , the most common being arthralgia (9.1%) ( Table IV) . Of 101 patients who received the drug via the peripheral venous route, 1 (1%) discontinued therapy because of a significant reaction or phlebitis. 23 The glycopeptides (e.g. vancomycin and teicoplanin), despite important shortcomings, served for more than 35 years as virtually the only antibacterials reliable for the treatment of infections due to multidrug-resistant Grampositive organisms. Vancomycin, in particular, is only slowly bactericidal against organisms such as staphylococci and often not bactericidal at all against enterococci. Moreover, neither of these glycopeptides penetrates well into the cerebrospinal fluid; high doses of vancomycin must be used if this drug is contemplated for the therapy of meningitis. 25 In addition, both drugs have the potential to cause nephrotoxicity especially in combination with aminoglycosides, and rapid intravenous infusion of vancomycin often produces symptomatic histamine release (the so-called 'red-man' syndrome). 26 The continuing increase in the prevalence of infections due to multidrug-resistant Gram-positive bacteria has important implications. There is clearly a need for antimicrobial agents with activity against multidrug-resistant Gram-positive bacteria. Quinupristin/dalfopristin is the first of a number of agents being developed for use in this setting. It is an innovative injectable antibiotic that has activity against the vast majority of strains of multidrug-resistant E. faecium, Staphylococcus aureus and coagulase-negative staphylococci, including VREF, methicillin-resistant S. aureus (MRSA) and glycopeptideintermediate S. aureus (GISA). 22 It is also active against virtually all strains of Streptococcus pneumoniae, including those with high-level resistance to penicillin and other -lactams. 22 The pharmacodynamic characteristics of quinupristin/dalfopristin (e.g. a prolonged post-antibiotic effect, 27 polymorphonuclear leucocyte/macrophage penetration and slow release) 28, 29 and its pharmacokinetic characteristics (e.g. active metabolites) allow the use of an 8 or 12 h dosing interval. As a result, quinupristin/ dalfopristin promises to play an important role in the treatment of patients with serious infectious disease, including those infected with bacteria resistant to many currently available antibiotics. The focused spectrum of activity of quinupristin/dalfopristin suggests that it will be particularly useful as a single agent in the treatment of monomicrobial infections or, in combination with an antibiotic having activity against Gram-negative pathogens, in the treatment of polymicrobial infections.
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